On December 6, 2022 RemedyBio, a Dublin based biotech company, inspired by functional biology for the discovery and development of new immune therapies using the power of its Nanoreactor Technology for the analysis of individual cells and cell interactions, reported their participation in INSPIRE, a €12.8 million lung cancer program (Press release, Remedy Biologics, DEC 6, 2022, View Source [SID1234644158]). In one of the largest ever grants for preclinical research in lung cancer, RemedyBio will collaborate with programme leader, OmniSpirant and other European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With the successful award of the grant by Horizon Europe, the INSPIRE consortium are already actively working on the program deliverables, and recently met in Galway, Ireland for the official kick off meeting. As well as OmniSpirant and RemedyBio, the consortium partners include Aerogen Limited (Ireland), Trinity College Dublin (Ireland), EVerZom (France), Biopharma Excellence (Pharmalex) (Germany), Deutsches Krebsforschungszentrum (DKFZ) (Germany) and Lung Cancer Europe (LuCE) (Switzerland).
Over the next 3 years, the INSPIRE programme aims to make an important and tangible impact on Europe’s Beating Cancer Plan and the EU Mission on Cancer. The consortium partners will work to develop a novel, effective and affordable lung cancer treatment via the development of a transformative new lower cost gene therapy. This project will place Europe as a leader in the fight against lung cancer and in the development of treatments for other debilitating lung diseases.
RemedyBio’s key role in the programme will be based on using RemedyBio’s proprietary Nanoreactor technology to investigate functional cell to cell interactions between the tumour and the gene therapy, building understanding of the efficacy of the new therapy.
"We are delighted to be part of the INSPIRE consortium in order to develop new and more effective therapies that impact patients lives", said Dan Crowley, CEO of Remedy Bio. "Our Nanoreactor technology and understanding of cell to cell interaction with help to drive insight and direction with our consortium partners in developing new RNA based therapeutics for lung cancer."